Savara Inc. (NASDAQ: SVRA) presented biomarker data from its IMPALA-2 Phase 3 clinical trial at the American Thoracic Society International ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE